Nanologica AB Net Assets
Nanologica AB net assets. Based on the latest financial reports, Nanologica AB (NICA) has net assets worth Skr97.50 Million SEK (≈ $10.49 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr262.32 Million ≈ $28.23 Million USD) and total liabilities (Skr164.82 Million ≈ $17.74 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore NICA net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr97.50 Million |
| % of Total Assets | 37.17% |
| Annual Growth Rate | 14.75% |
| 5-Year Change | -56.11% |
| 10-Year Change | 2.77% |
| Growth Volatility | 653.28 |
Net Assets of Nanologica AB (2012–2025)
Net assets of Nanologica AB from 2012 to 2025. This chart illustrates how Nanologica AB's net assets have evolved over time, based on quarterly financial data. See NICA net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Nanologica AB (2012–2025)
The table below shows the annual net assets of Nanologica AB from 2012 to 2025. For live market cap and overall valuation, see Nanologica AB (NICA) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr22.64 Million ≈ $2.44 Million |
-69.45% |
| 2024-12-31 | Skr74.11 Million ≈ $7.98 Million |
+4004.74% |
| 2023-12-31 | Skr-1.90 Million ≈ $-204.26K |
-102.59% |
| 2022-12-31 | Skr73.16 Million ≈ $7.87 Million |
+41.79% |
| 2021-12-31 | Skr51.60 Million ≈ $5.55 Million |
-44.50% |
| 2020-12-31 | Skr92.97 Million ≈ $10.00 Million |
+2155.89% |
| 2019-12-31 | Skr4.12 Million ≈ $443.48K |
-82.62% |
| 2018-12-31 | Skr23.71 Million ≈ $2.55 Million |
+1123.13% |
| 2017-12-31 | Skr1.94 Million ≈ $208.60K |
-91.20% |
| 2016-12-31 | Skr22.03 Million ≈ $2.37 Million |
-8.72% |
| 2015-12-31 | Skr24.14 Million ≈ $2.60 Million |
+195.79% |
| 2014-12-31 | Skr8.16 Million ≈ $878.25K |
-23.43% |
| 2013-12-31 | Skr10.66 Million ≈ $1.15 Million |
+181.53% |
| 2012-12-31 | Skr3.79 Million ≈ $407.43K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nanologica AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 41752281100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Nanologica AB Net Assets Breakdown (December 2025)
Nanologica AB net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr4.51 Million | 19.90% |
| Other Components | Skr442.05 Million | 1952.10% |
| Total Equity | Skr22.64 Million | 100.00% |
Nanologica AB Competitors by Market Cap
The table below lists competitors of Nanologica AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Spectrumone publ AB
ST:SPEONE
|
$5.98 Million |
|
GR BUSSINES SO
F:INW
|
$5.98 Million |
|
Kelso Technologies Inc
TO:KLS
|
$5.99 Million |
|
Nacon S.A.
PA:NACON
|
$5.99 Million |
|
Dongil Steel Co. Ltd
KQ:023790
|
$5.98 Million |
|
SKAKO A/S
CO:SKAKO
|
$5.97 Million |
|
Beasley Broadcast Group Inc
NASDAQ:BBGI
|
$5.97 Million |
|
Manhattan Corporation Ltd
AU:MHC
|
$5.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanologica AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 74,112,000 to 22,645,000, a change of -51,467,000 (-69.4%).
- Net loss of 51,289,000 reduced equity.
- New share issuances of 38,000 increased equity.
- Other comprehensive income increased equity by 999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-51.29 Million | -226.49% |
| Share Issuances | Skr38.00K | +0.17% |
| Other Comprehensive Income | Skr999.00 | +0.0% |
| Other Changes | Skr-217.00K | -0.96% |
| Total Change | Skr- | -69.44% |
Book Value vs Market Value Analysis
This analysis compares Nanologica AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.66x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.05x to 0.66x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Skr3.39 | Skr0.17 | x |
| 2013-12-31 | Skr7.40 | Skr0.17 | x |
| 2014-12-31 | Skr2.38 | Skr0.17 | x |
| 2015-12-31 | Skr6.61 | Skr0.17 | x |
| 2016-12-31 | Skr5.84 | Skr0.17 | x |
| 2017-12-31 | Skr0.42 | Skr0.17 | x |
| 2018-12-31 | Skr1.43 | Skr0.17 | x |
| 2019-12-31 | Skr0.24 | Skr0.17 | x |
| 2020-12-31 | Skr3.84 | Skr0.17 | x |
| 2021-12-31 | Skr1.82 | Skr0.17 | x |
| 2022-12-31 | Skr2.40 | Skr0.17 | x |
| 2023-12-31 | Skr-0.05 | Skr0.17 | x |
| 2024-12-31 | Skr1.50 | Skr0.17 | x |
| 2025-12-31 | Skr0.26 | Skr0.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanologica AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -226.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -242.77%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 3.89x
- Recent ROE (-226.49%) is below the historical average (-195.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -133.01% | -141.30% | 0.55x | 1.71x | Skr-5.41 Million |
| 2013 | -105.89% | -212.36% | 0.34x | 1.46x | Skr-11.01 Million |
| 2014 | -180.42% | -894.90% | 0.08x | 2.40x | Skr-15.54 Million |
| 2015 | -59.20% | -438.02% | 0.10x | 1.36x | Skr-16.70 Million |
| 2016 | -101.93% | -1122.76% | 0.06x | 1.45x | Skr-24.66 Million |
| 2017 | -1036.69% | -772.94% | 0.10x | 13.37x | Skr-20.29 Million |
| 2018 | -88.11% | -503.92% | 0.12x | 1.45x | Skr-23.26 Million |
| 2019 | -521.07% | -209.97% | 0.24x | 10.26x | Skr-21.89 Million |
| 2020 | -26.70% | -153.86% | 0.11x | 1.57x | Skr-34.12 Million |
| 2021 | -97.16% | -388.20% | 0.13x | 1.91x | Skr-55.29 Million |
| 2022 | -75.30% | -3542.77% | 0.01x | 2.11x | Skr-62.41 Million |
| 2023 | 0.00% | -5208.39% | 0.02x | 0.00x | Skr-74.97 Million |
| 2024 | -88.55% | -451.43% | 0.10x | 1.93x | Skr-73.04 Million |
| 2025 | -226.49% | -242.77% | 0.24x | 3.89x | Skr-53.55 Million |
Industry Comparison
This section compares Nanologica AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,646,968
- Average return on equity (ROE) among peers: -44.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanologica AB (NICA) | Skr97.50 Million | -133.01% | 1.69x | $5.98 Million |
| 2cureX AB (2CUREX) | $5.10 Million | -80.96% | 0.52x | $1.13 Million |
| Ascelia Pharma AB (publ) (ACE) | $237.06 Million | -16.83% | 0.06x | $7.59 Million |
| AcouSort AB (ACOU) | $33.02 Million | -37.49% | 0.11x | $7.24 Million |
| Active Biotech AB (ACTI) | $380.27 Million | -78.60% | 0.23x | $11.35 Million |
| Alzinova AB (ALZ) | $1.55 Million | -30.37% | 0.38x | $7.47 Million |
| AlzeCure Pharma (ALZCUR) | $26.18 Million | -134.56% | 0.32x | $78.65 Million |
| Annexin Pharmaceuticals AB (ANNX) | $24.93 Million | -147.97% | 0.21x | $5.07 Million |
| Alligator Bioscience AB (ATORX) | $617.96 Million | -10.32% | 0.04x | $1.24 Million |
| BioInvent International AB (BINV) | $159.63 Million | 0.00% | 0.22x | $30.45 Million |
| BioArctic AB (publ) (BIOA-B) | $60.76 Million | 94.77% | 10.65x | $2.48 Billion |
About Nanologica AB
Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange prod… Read more